Datametrex - CEO, Marshall Gunter.
CEO, Marshall Gunter.
Source: LinkedIn
  • Datametrex AI (DM) subsidiary, Medi-Call, has created a new subscription plan
  • Patients can pick which type of healthcare service they need and not pay for additional treatments that do not suit their healthcare needs
  • This new membership plan brings affordability and accessibility to younger students who may only need basic telehealth services
  • Medi-call is a subscription-based software-as-a-service (SaaS) mobile application that connects patients with doctors
  • Datametrex AI utilizes artificial intelligence (AI) to create solutions for the cyber security, telehealth, and electric vehicle (EV) verticals
  • Datametrex AI Limited (DM) is trading at C$0.08 per share at 11 am ET

Datametrex AI (DM) subsidiary, Medi-Call Inc., has created a new subscription plan designed to meet the needs of more Canadians.

Creating more membership plans means patients can pick which type of healthcare service they need and not pay for additional treatments that do not suit their healthcare needs.

This new membership plan brings affordability and accessibility to younger students who may only need basic telehealth services such as physician virtual visits, doctor notes and prescriptions.

Marshall Gunter, CEO of Datametrex, commented on the news.

“Our mission is to provide easy access to healthcare to everyone. No long wait times for a physician, just healthcare on our watch. Our modular, affordable membership plans cater to different needs and lifestyles, allowing patients to get more out of their telehealth experience.”

Medi-call is a subscription-based software-as-a-service (SaaS) mobile application that connects patients with doctors.

Datametrex AI Limited is a technology-focused company using artificial intelligence (AI) to create solutions for the cyber security, telehealth, and electric vehicle (EV) verticals.

Datametrex AI Limited (DM) is trading at C$0.08 per share at 11 am ET.


More From The Market Online

This AI tech stock is growing exponentially: What you need to know

AI tech stock Metaguest.AI (CSE:METG) grows subscription sales and experience bookings by almost 10x since Q1 2023.
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

4 stocks to consider after Microsoft’s 2024 study on AI at work

Microsoft (NASDAQ:MSFT) on Wednesday released the 2024 Work Trend Index, which looks into the state of artificial intelligence at work.